Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MRK, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Berahyaluronidase Alfa and Pembrolizumab… FDA approved Sep 2025 · Keytruda Qlex |
Non-small Cell Lung Cancer | Phase 3 · NCT07431827 | Recruiting |
| Pembrolizumab FDA approved Sep 2014 · Keytruda |
Carcinoma, Non-Small-Cell Lung | Phase 3 · NCT06623422 | Recruiting |
| Sotatercept FDA approved Mar 2024 · Winrevair |
Pulmonary Hypertension | Phase 3 · NCT07839585 | Not yet recruiting |
| Belzutifan FDA approved Aug 2021 · Welireg |
Malignant Neoplam | Phase 2 · NCT07793942 | Recruiting |
| Fluorouracil | Bladder Cancer | Phase 3 · NCT07829783 | Recruiting |
| Calderasib (MK-1084) | Non-small Cell Lung Cancer | Phase 3 · NCT07431827 | Recruiting |
| Doxorubicin | Breast Neoplasms | Phase 3 · NCT06966700 | Recruiting |
| Resiquimod Sulfate (EIK1001) | Non Small Cell Lung Cancer (Squamous or Non Squamous) | Phase 2/3 · NCT07365319 | Recruiting |
| Enlicitide | Hyperlipidemia | Phase 3 · NCT07216482 | Completed |
| Ensifentrine | Pulmonary Disease, Chronic Obstructive | Phase 3 · NCT07874815 | Recruiting |
| Epirubicin | Breast Neoplasms | Phase 3 · NCT06966700 | Recruiting |
| H1 receptor antagonist | Ovarian Cancer | Phase 3 · NCT06824467 | Recruiting |
| Histamine-2 Receptor Antagonist | Ovarian Cancer | Phase 3 · NCT06824467 | Recruiting |
| Intismeran Autogene | Non-small Cell Lung Cancer | Phase 3 · NCT07513376 | Recruiting |
| IV Tulisokibart | Crohn's Disease | Phase 3 · NCT06430801 | Recruiting |
| MMC | Bladder Cancer | Phase 3 · NCT07829783 | Recruiting |
Also used in these trials (approved or third-party drugs, not MRK's own candidates): Abiraterone Acetate, Acalabrutinib, Acetaminophen, Bevacizumab, Capecitabine, Carboplatin, Cisplatin, Cladribine, Cyclophosphamide, Dexamethasone, Docetaxel Anhydrous, Enzalutamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MRK holds $11.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MRK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 228,073,244 | 9.25% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 186,323,766 | 7.56% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 121,422,392 | 4.93% | 2026-09-30 |
| Wellington Management Group, LLP | Institution (13F) | 71,664,541 | 2.91% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 68,109,899 | 2.76% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 61,565,702 | 2.50% | 2026-09-30 |
| Charles Schwab Investment Management, In | Institution (13F) | 50,826,533 | 2.06% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 48,234,438 | 1.96% | 2026-09-30 |
| FMR, LLC | Institution (13F) | 46,222,051 | 1.87% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 43,115,332 | 1.75% | 2026-09-30 |
| Robert M Davis Chairman, CEO & President, Director · +187,421 options |
Insider | 450,351 | 0.02% | 2026-05-05 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth · +46,855 options |
Insider | 114,291 | 0.00% | 2026-11-12 |
Share count 2,465,245,688 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-12 filed 2026-11-16 |
DeLuca Richard R. |
Option exercise (M) | 58,185 | $77.62 | 171,140 |
| 2026-11-12 filed 2026-11-16 |
DeLuca Richard R. |
Sale (S) | 58,185 | $148.01 | 112,955 |
| 2026-11-12 filed 2026-11-16 |
DeLuca Richard R. |
Option exercise (M) | 58,185 | – | – |
| 2026-11-01 filed 2026-11-03 |
DIAZ PAUL J |
Option award (A) | 613 | $149.52 | – |
| 2026-09-30 filed 2026-10-01 |
Karsanbhai Surendralal Lanca |
Option award (A) | 112 | $145.31 | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MRK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →